← All trials
NCT06082960
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 9, 2023
- Primary completion
- Nov 30, 2026
- Completion date
- Nov 30, 2026
- First posted
- Oct 13, 2023
- Last posted
- Dec 7, 2023
- Enrollment
- 120
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gilead SciencesLead sponsor
- Gilead SciencesStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.